🇺🇸 FDA
Pipeline program

E7090

E7090-J000-201

Phase 2 small_molecule completed

Quick answer

E7090 for Cholangiocarcinoma is a Phase 2 program (small_molecule) at Eisai Co., with 1 ClinicalTrials.gov record(s).

Program details

Company
Eisai Co.,
Indication
Cholangiocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials